IDO1 and neoplasm: Since the identification of IDO1 as a potential drug target and a key mediator of tumor immune escape, efforts to develop small-molecule inhibitors have intensified (Munn et al., 1998), with inhibitors now commonly classified into four types by their catalytic-site interaction (Röhrig et al., 2019) (see Figure 1C).